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ABSTRACT 
The transformation of a normal cell into a cancer cell involves the 
accumulation of somatic DNA alterations that confer growth and survival 
advantages. These genomic alterations can be different in terms of pattern 
and size, comprising single nucleotide variants (SNVs), small insertions or 
deletions (indels), structural variations (SVs) or foreign DNA insertions such 
as viral DNA. Cancer genomes typically harbor numerous such changes, of 
which only small fractions are driver events that are positively selected for 
during the evolution of the tumor. High throughput sequencing has enabled 
systematic mapping of somatic DNA alterations across thousands of tumor 
genomes. Mutations in particular have been thoroughly explored in this type 
of data, and this has implicated many new genes in tumor development. 
However, our knowledge remains more limited when it comes to the 
contribution of SVs to cancer. In the present thesis, we made use of publicly 
available cancer genomics data to gain further insight into the role of 
structural genomic alterations in tumor development.  
Viruses cause 10-15% of all human cancers through multiple mechanisms, 
one of which is structural genomic changes due to viral DNA being 
integrated into the human genome. Thus, in the first study, we performed an 
unbiased screen for viral genomic integrations into cancer genomes. We 
developed a computational pipeline using RNA-Seq data from ~4500 tumors 
across 19 different cancer types to detect viral integrations. We found that 
recurrent events typically involved known cancer genes, and were associated 
with altered gene expression.  
SVs can lead to copy number amplification of specific cancer driver genes, as 
well as the formation of fusion oncogenes, but their importance in cancer 
beyond these types of events is underexplored. We mapped SVs to the human 
genome using whole genome sequencing data from 600 tumors across 18 
 different cancer types and investigated the global relationship between SVs 
and mRNA changes. We found that such events often contribute to altered 
gene expression in human tumors, but we were not able to detect novel 
recurrent driver events. To increase the cohort size, we used a larger but 
lower resolution and more limited dataset, comprising of microarray based 
DNA copy number profiles from ~10,000 tumors across 32 cancer types, 
with the aim of identifying recurrent SV driver events in tumors. Specifically, 
we investigated SVs predicted to result in promoter substitution events, a 
known mechanism for gene activation in cancer, and found several recurrent 
activating events with potential cancer driver roles. Notable among our 
findings in all the studies were human papillomavirus integrations 
in RAD51B and ERBB2 and gene fusions involving NFE2L2, TIAM2 and 
SCARB1, all being known cancer genes. 
Taken together, massive amounts of genomic and transcriptomic sequencing 
data allowed us to comprehensively map viral integrations and structural 
variations in cancer, which led to the identification of several genes with 
potential roles in tumor development. 
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SAMMANFATTNING PÅ SVENSKA 
Transformationen från en vanlig cell till en cancercell involverar somatiska 
DNA-förändringar som ger tillväxt- och överlevnadsfördelar. Dessa DNA-
förändringar kommer i många olika former, och innefattar typer som SNV 
(från eng. single nucleotide variants), insertioner och deletioner (gemensamt 
benämnda indels), strukturella variationer (SV), samt insertioner av 
främmande DNA, såsom viralt DNA. Ett cancergenom bär vanligtvis på 
många sådana förändringar, men bara ett fåtal av dessa är cancerdrivande och 
har selekteras fram under tumörens utveckling. High throughput sequencing 
har möjliggjort systematisk kartläggning av somatiska DNA-förändringar i 
tusentals tumörgenom. Mutationer har undersökts särskilt noga i denna typ av 
data, med resultatet att många nya gener har knutits till tumörutveckling. Till 
skillnad från mutationer så är kunskapen om hur SV bidrar till cancer mer 
begränsad. I denna avhandling har vi använt oss av publikt tillgängliga 
cancergenomikdata för att fördjupa vår förståelse av strukturella 
genomförändringars roll i tumörutveckling. 
Virus orsakar 10–15 % av alla cancerfall hos människor genom flera 
mekanismer, varav en är strukturella genomförändringar orsakade av 
integrering av viralt DNA i det mänskliga genomet. Därför utförde vi i den 
första studien en sökning efter integrerat viralt DNA i cancergenom. Vi 
utvecklade en beräkningspipeline som använder sig av RNA-Seq-data från 
~4500 tumörer från 19 olika cancertyper för att detektera virala integrationer. 
Vi fann att återkommande integrationer vanligtvis involverade kända 
cancergener, samt var associerade med förändrat genuttryck. 
SV kan leda till kopietalsökning av specifika drivande cancergener samt 
bildning av fusions-onkgener, men utöver detta är det mer oklart i vilken 
utsträckning de bidrar till cancer. Vi kartlade SV i det mänskliga genomet 
med hjälp av helgenomsekvenseringsdata från 600 tumörer från 18 olika 
cancertyper, och undersökte sambandet mellan SV och mRNA-förändringar. 
Vi fann att SV ofta bidrar till förändrat genuttryck i mänskliga tumörer, men 
hittade inga nya cancerdrivande förändringar. Med målet att finna nya 
cancerdrivande SV ökade vi kohortstorleken genom att använda ett större 
men mer lågupplöst och begränsat dataset, bestående av microarray-baserade 
DNA-kopietalsprofiler från ~10 000 tumörer från 32 cancertyper. Vi 
undersökte SV som förväntades orsaka växling av promotorer gener emellan 
- en känd mekanism för genaktivering i cancer - och hittade flera 
återkommande aktiverande SV med potentiellt cancerdrivande egenskaper. 
 Av särskilt intresse i våra resultat var integrationer av humant papillomvirus i 
RAD51B och ERBB2, samt fusionsgener som involverar NFE2L2, TIAM2 
och SCARB1 – alla kända cancergener. 
Sammantaget möjliggjorde enorma mängder genom- och 
transkriptsekvenseringsdata en omfattande kartläggning av virala 
integrationer och strukturella variationer i cancer, vilket resulterade i 
identifiering av ett flertal gener med potentiella roller i tumörutveckling. 
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1 INTRODUCTION 
1.1 Biology of Cancer 
Normal cell division is a tightly regulated and highly coordinated process. 
When cells break free of these controls, they can begin to divide 
uncontrollably resulting in accumulation of cells, which if left to grow 
continuously, forms a tumor. There are two main classifications of tumors: a 
benign tumor, which does not attack the neighboring cells or tissues, and 
malignant tumors that are highly invasive and may eventually spread 
throughout the body (Weinberg 2007). Benign tumors are rarely life 
threatening, unless they block a vital access path such as a blood vessel, 
whereas malignant cells can infiltrate other organs and more readily cause 
fatal damage. Typically, “cancer cells” would refer to malignant rather than 
benign cells. 
The transformation a normal cell to a cancer cell is an evolutionally process. 
It includes continuous acquisition of alterations in the cellular DNA of 
somatic cells and selection acting on alterations that confer fitness advantages 
to cells (Stratton, Campbell and Futreal 2009). Genomic alterations occur 
randomly all over the genome, however only a small fraction of alterations 
become beneficial for tumor growth, typically affecting two groups of genes 
known as oncogenes and tumor suppressor genes (Yarbro 1992). 
1.1.1 Proto-oncogene and Oncogenes 
Cells contain many proteins that promote cell division. As known from the 
central dogma of molecular biology, the code for creating these proteins is in 
the sequences in the cellular DNA called genes (Box 1). The normal forms of 
genes coding for such proteins are called proto-oncogenes. Alterations in 
these genes may further activate them, stimulating excessive division in the 
cell. Proto-oncogenes with “gain of function” alterations are called 
oncogenes (Anderson et al. 1992). They are involved in multiple hallmarks of 
cancer (see section 1.1.3). One of the most frequently activated oncogenes in 
malignant cells is TERT, a telomerase subunit, which plays an important role 
in cellular immortalization (Heidenreich et al. 2014).  
Oncogenes can be categorized into several groups: (1) Growth factors, which 
can increase the cell proliferative capabilities (Witsch, Sela and Yarden 
2010); (2) Receptor tyrosine kinases (RTKs), which are part of many key cell 
signaling pathways regulating cell proliferation. Several RTK subfamilies are 
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known for their direct contribution to cancer development, one of which are 
the epidermal growth factor receptors (EGFRs). Overexpression of genes in 
this family including HER1 (also known as EGFR) and HER2 (also known as 
ERBB2) have been seen in wide range of cancers, as a result of both 
activating mutations and amplifications (Voldborg et al. 1997, McKay et al. 
2002, Mitri, Constantine and O'Regan 2012); (3) Transcription factors, which 
are responsible for the regulation of genes involved in several cellular 
pathways including proliferation. The ETS factor gene family is one of the 
largest families of transcription factors that are crucial for tumor 
development. They are involved in several cellular mechanisms such as cell 
proliferation, apoptosis, and angiogenesis, all of which are key hallmarks of 
cancer. ETS factors are sometimes activated in tumors by hijacking the 
strong promoters of highly expressed genes as a consequence of genomic 
rearrangements (Ida et al. 1995, Peeters et al. 1997, Tomlins et al. 2005). 
Additionally, another well established transcription factor involved in cancer 
is MYC that plays a critical role in cell cycle progression, apoptosis and 
cellular transformation (Dang 2012). Several types of genomic alterations, 
including point mutations, amplifications, and structural alterations (see 
section 1.2) contribute to the activation of MYC in cancer (Finver et al. 1988, 
Escot et al. 1986, Gabay, Li and Felsher 2014, Affer et al. 2014); (4) 
GTPases, which play a major role in cell signaling transduction. The Ras 
gene family, which is frequently activated in cancer, is responsible for 
switching on cell growth independent from growth factors (Goodsell 1999). 
Ras genes including KRAS, NRAS, and HRAS are mainly activated in cancer 
through point mutations (Fernandez-Medarde and Santos 2011).  
Box 1. Central dogma of molecular biology (Crick 1958) 
DNA stores all the genetic information in human cells. DNA is made of 
billions of chemical building blocks called nucleotides. Replication is the 
mechanism of making two near-identical copies of the DNA as cells 
divide into two daughter cells. Sections of the DNA, known as genes, 
contain the instructions for making different proteins in the cell. Genes 
are first synthesized into molecules called RNA through a process called 
transcription. RNA, like DNA, is made of nucleotides. RNAs then are 
translated into proteins that are the fundamental components of the cell. 
Proteins are made of chains of amino acids, each one determined by a 
group of three nucleotides in the corresponding gene. 
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1.1.2 Tumor suppressors 
Tumor suppressor (TS) genes are defined as genes that inhibit the growth and 
division of the cell (Friend et al. 1986). They code for proteins whose 
function is to act as a “brake” in the cell cycle (Box 2). Mutations in these 
genes may lead to the production of proteins that have lost the “brake” 
function, allowing the cell to continue to grow. These mutations are known as 
“loss of function” mutations. Each cell in human body contains two copies of 
each gene. One functional copy of a tumor suppressor gene is normally 
enough to regulate cell division. However, once both copies become mutated, 
the cell cycle brakes no longer work and therefore, the cell can start to 
proliferate excessively.  
 
In 1961, Knudson discovered the first TS gene, RB1, and proposed the “two-
hit” model (Knudson 1971) that was ultimately established in 1986 (Friend et 
al. 1986). RB1 is responsible for preventing unnecessary cell growth during 
cell cycle. Loss of function mutations in RB1 are associated with tumor 
growth in many cancer types (Sherr and McCormick 2002). Another 
predominant tumor suppressor is TP53, which is mutated in around 50% of 
all cancers. TP53 stops cells with damaged DNA from growing by two key 
mechanisms, either by halting the cell cycle or by initiating apoptosis 
(Olivier, Hollstein and Hainaut 2010). 
Box 2. Cell cycle   
The cell cycle is a chain of events in the cells resulting in division of one 
cell into two daughter cells with two identical DNAs copies of its own 
cellular DNA. The eukaryotic cell cycle has four different phases gap 1, 
synthesis, gap 2, and mitosis (G1, S, G2, and M respectively). The S 
phase is when the DNA is duplicated and two newly synthesized cellular 
DNAs are produced, the M is when the cell physically divides into two 
daughter cells, and the G1, G2 phases are gap phases involving several 
checkpoints in which cells ensure that they are ready to enter the S and 
M phases respectively. 
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TS genes can be classified into three classes based on the primary function of 
the proteins they encode: (1) Anti-oncogenes, such as CDKN2A and RB1, 
which inhibit the pro-growth activities of oncogenes like CDK4 and CCND1 
(Serrano, Hannon and Beach 1993); (2) DNA damage checkpoint genes such 
as TP53; (3) Caretaker genes, such as BRCA1 that help to maintain genomic 
stability (Yoshida and Miki 2004). Many TS genes have more than one 
function and could be classified in more than one of the categories mentioned 
above.  
1.1.3 Hallmarks of Cancer 
Several distinctive biological machineries are accountable for the 
transformation of a normal cell to a tumor cell. These mechanisms can be 
summarized into 10 biological hallmarks known as the hallmarks of cancer 
(Hanahan and Weinberg 2000, Hanahan and Weinberg 2011b) shown in Fig. 
1. There are six primary hallmarks, two enabling hallmarks and two emerging 
hallmarks, which will be described in more detail below.  
Self-sufficiency in Growth Signals 
Cell division is controlled by growth factors. Growth factors are proteins in 
the cell that are responsible for sending signals to other cells to start the 
Figure 1: Hallmarks of cancer. Adapted from (Hanahan and Weinberg 2011b) 
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replication process (Paul et al. 1978). They bind to growth factor receptors, 
which are proteins sitting in the cell membrane. Growth factors activate the 
receptors by binding to them, leading to a cascade of signals within the cell, 
signaling that it should divide. The cascade is a series of interactions between 
numerous proteins in the cell. In a cancer cell, genetic alterations in the genes 
coding for these receptors can disrupt this highly regulated process. Such 
alterations can result in the increased activation of a number of genes leading 
to excessive transcription and increased signaling from the receptors. 
Alternatively, alterations may result in the formation of new receptors, which 
activates themselves without the presence of growth factors (Normanno et al. 
2006). Growth factor-independent signaling in cancer cells causes 
uncontrolled cell division and therefore may result in tumor formation. 
Insensitivity to Anti-growth Signals 
There are multiple checkpoints at the end of each phase in the cell cycle, 
where any cell with damaged DNA is detected. Normal cells with defective 
DNA usually activate the cell death mechanism before they enter mitosis 
(Cuddihy and O'Connell 2003). TS genes code for the proteins that are 
responsible for stopping cells with damaged DNA from dividing. In a cancer 
cell, alterations in TS genes may inactivate these checkpoints, allowing the 
damaged cells to divide and pass their mutated DNA to their daughter cells. 
Limitless Replicative Potential 
Most cells are limited to 40-60 replication cycles (Hayflick 1965). This is 
regulated through a mechanism called telomere shortening. Telomeres are 
long repetitive sequences located at the ends of each chromosome which 
protect the chromosomes from nucleolytic degradation and inter-
chromosomal fusions (Witzany 2008). In a normal cell, telomere ends 
become shorter after each replication cycle, and once it reaches a critical 
limit, the cell usually undergoes cellular senescence, a mechanism by which 
cells stop diving (Hayflick and Moorhead 1961). However, by maintaining 
the length of their telomers, cancer cells can evade the Hayflick limit. This 
typically happens through the activation of a protein called telomerase 
(Nosek, Kosa and Tomaska 2006), which adds DNA bases to the telomeres. 
Telomerase is typically inactive in normal differentiated cells, whereas in 
cancer cells it may become activated, for example by mutations or SVs (see 
section 3.3.2). 
Evading Apoptosis  
The word apoptosis comes from the Greek meaning “falling off”. It is a 
normal process, in which cells deliberately kill themselves for the good of the 
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organism (Green 2011). Apoptosis can be triggered by an intrinsic pathway 
inside the cell like DNA damage, or by extrinsic events such as the lack of 
nutrients and growth factors outside the cell. Like all the other biological 
processes, apoptosis involves many proteins with both pro- and anti-apoptotic 
properties (Silke and Meier 2013). 
Cancer cells need to avoid apoptosis to ensure their survival (Fernald and 
Kurokawa 2013). Genetic alterations in cancer cells not only increase cellular 
growth, but may also lead to the loss of apoptosis. In some cancer cells, there 
is a resistance to apoptosis due to activation of anti-apoptotic genes, for 
example due to mutations in these genes (Yip and Reed 2008). Conversely, 
deactivating mutations in pro-apoptotic proteins could potentially prevent the 
cell from entering apoptosis (Lee et al. 2004). The TP53 gene, known as “the 
guardian of the genome” plays an important role in detecting DNA damage 
and signaling to the cell to initiate the repair. Apoptosis is induced in cases 
where the DNA could not be repaired. TP53 deactivation through genomic 
alterations is the most frequent driving event in cancer (Olivier et al. 2010).  
Activating Invasion and Metastasis 
Normal cells grow in a well-organized manner where they form tissues and 
ultimately organs with specific functions. Conversely, malignant cells 
typically invade the surrounding tissues to find the nutrients they need to 
survive and sustain their growth. The ability of the cancer cells to break free 
of their own tissue, enter the blood vessels and reside in another tissue is 
called metastasis (Gupta and Massague 2006). This is a very complex 
process, which involves interaction between several proteins. Dysregulation 
of such proteins by genomic alterations could potentially give cells metastatic 
capabilities. 
Sustained Angiogenesis 
As the tumor grows it needs additional nourishments to maintain its 
proliferation. Therefore, it requires the recruitment of new blood vessels as 
they are the main oxygen and nutrients supply. This can be achieved by a 
mechanism that stimulates the growth of the blood vessels into and around 
the tissue called angiogenesis (Nishida et al. 2006, Carmeliet and Jain 2000). 
This machinery is active at specific times in normal conditions such as 
wound healing. One of the major stimulators of angiogenesis is a protein 
called vascular endothelial growth factor known as VEGF (Leung et al. 
1989). Overexpression of this protein, acquired by genomic alterations, is one 
of the mechanisms activating angiogenesis. 
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Genome Instability  
The six characteristics mentioned so far, known as the “primary hallmarks” 
of cancer, allow cancer cells to survive, proliferate and transfer irregularly 
within the body. The mechanisms that allow cancer cells to acquire these 
primary hallmarks are known as “enabling hallmarks". One of these enabling 
characteristics is genomic instability, which results in a large number of 
genomic alterations. These alterations could become beneficial for tumors by 
orchestrating the primary hallmarks of cancer (Negrini, Gorgoulis and 
Halazonetis 2010).   
Mutations in genes involved in the DNA maintenance machinery, recognized 
as caretakers, have often been observed in context of cancer. These caretaker 
genes are involved in several mechanisms, one of which is to detect DNA 
damage and activate the repair mechanism. Inactivating mutations in these 
genes are associated with increased genomic instability and therefore play an 
important role in cancer progression (Barnes and Lindahl 2004, Korkola and 
Gray 2010). 
Tumor Promoting Inflammation 
Another enabling hallmark of cancer is tumor-promoting inflammation. 
Inflammation is a complex biological response triggered in the presence of 
harmful stimuli. There are two types of inflammation: acute and chronic. 
While acute inflammation is typically protective, chronic inflammation 
caused by the continuous persistence of an infectious agent is associated with 
cancer development. Chronic inflammation can contribute to cancer 
progression by affecting multiple hallmarks of cancer. These include 
providing growth factor to sustain proliferative capabilities, pro-angiogenesis 
enzymes (Grivennikov, Greten and Karin 2010), and inducing cellular stress 
that can damage the DNA (Visconti and Grieco 2009).  
Evading the Immune System  
Progress in cancer research in the last decades has added two emerging 
hallmarks to the list of general characteristics of cancer cells, which are 
beneficial to the growth, and survival of the cancer. The immune system has 
many mechanisms that prevent it from attacking self cells. However, the 
immune response to cancer cells involves self-attacking cells with abnormal 
metabolism and growth, a mechanism called cancer immunoediting (Dunn et 
al. 2002). Immunoediting encompasses three phases: elimination, equilibrium 
and escape (Dunn, Old and Schreiber 2004). Elimination refers to the first 
phase also known as immune surveillance, during which the tumor cells, by 
releasing tumor associated antigen, can be recognized by immune system and 
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are therefore eradicated. In the equilibrium phase, cells with continuous DNA 
alterations, eventually acquire a non-immunogenic phenotype and are 
positively selected for during the evolution of the tumor. Finally, during the 
escape phase, those cells that survived the elimination and equilibrium phases 
grow uncontrollably leading to the formation of noticeable tumors.  
Abnormal Metabolic Pathways 
Energy and nutrients are necessary for cells to grow. Cancer cells grow 
uncontrollably and to sustain their proliferation capacity, they need an 
increased uptake of nutrients such as glucose, which can be achieved by 
adjusting their metabolism (Lunt and Vander Heiden 2011). Cancer cells, 
unlike most normal cells, tend to metabolize glucose and produce energy 
through biochemical pathways that do not involve oxygen even when it is 
available. This phenomenon is known as Warburg effect (Warburg, Wind and 
Negelein 1927). While this is an inefficient metabolic pathway, malignant 
cells typically produce ATP that is the primary energy carriers, up to 100 
times faster than healthy cells.  
1.1.4 Cell signaling and cancer 
Cell signaling is a part of a complex communication process that manages 
basic cellular activities. Three stages are involved in cell signaling: reception, 
transduction and response. Reception is when the cell recognizes the 
signaling molecule through proteins called receptors. Transduction is when 
the receptor protein transmits the signal further through a series of molecular 
events, thereby initiating a cellular response, and response is when different 
cellular activities are triggered such as cell growth, expression, cell death and 
so on. Errors in signaling pathways may result in diseases such as cancer. 
All the hallmarks of cancer discussed above arise as modifications in several 
signaling pathways that are responsible for the regulation of diverse cellular 
activities in normal cells (Martin 2003). One of the key protein families 
involved in such cellular processes including cell growth is receptor tyrosine 
kinases (RTKs). Abnormal signaling by RTKs, such as EGFR and HER2, 
(see section 1.1.2) have been shown to be critically involved in cancer 
progression (Zwick, Bange and Ullrich 2001). 
1.1.5 Tumor viruses  
Rous sarcoma virus (RSV) was the first virus discovered to be associated 
with cancer development. In 1911, Peyton Rous injected a cell free extract of 
a chicken sarcoma tumor into healthy chickens and observed that they 
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developed tumors (Rous 1911). He concluded that the carcinogenic agent 
passed on to the healthy chickens might have been a virus, which was later 
established and named RSV. Since the discovery of RSV, seven types of 
viruses have been found to be responsible for 10-15% of all human cancers 
(Table 1). Viral oncogenicity involves multiple mechanisms. Direct 
mechanisms include expression of viral oncogenes (EVO) and integration of 
viral DNA (IVD) into the host DNA by which they either facilitate the 
expression of their own oncogenes or promote the expression of already 
existing proto-oncogenes in the host DNA. Additionally, viruses can induce 
chronic inflammation (ICI) sometimes even after decades of acute infection 
indirectly enabling tumor growth.  
Table 1: Human tumor associated viruses. DS: double strand. SS: single strand. C: 
circular. L: linear 
Virus Cancer type Mechanism Virus Type 
HBV Hepatocellular  ICI, IVD, EVO DS C DNA 
HCV Hepatocellular  ICI SS L RNA 
EBV (HHV4) Subset of lymphomas  EVO DS L DNA 
HPV Cervical, Oral cavity IVD, EVO DS C DNA 
HTLV-1 T-cell leukemia ICI, IVD SS L RNA 
KSHV (HHV8) Sarcoma, lymphoma  EVO DS C DNA 
MCV Merkel cell  
 
IVD DS C DNA 
 
DNA viruses store their genetic materials in DNA. 5/7 reported human tumor 
viruses are DNA viruses. They typically utilize the cellular replication 
mechanism to ensure their own replication occurs (Munger et al. 2004). 
Human papilloma virus (HPV), a DNA virus typically infecting the genital 
tissues, promotes carcinogenesis by integrating its DNA into the human 
genome leading to the expression of the E6 and E7 viral oncogenes that 
inactivate the TP53 and RB tumor suppressor genes respectively (zur Hausen 
2002). Additionally, MYC activation is shown to be associated with HPV 
viral integration into the cellular DNA particularly in the MYC region (Peter 
et al. 2006). Another DNA tumor virus is Epstein-Barr virus (EBV), which 
normally infects B-cells of the immune system. It encodes three viral 
oncogenes, LMP1, EBNA-2 and EBNA-3C that are essential for B-cell 
growth, transformation and the disruption of cellular signaling pathways 
(Arvanitakis, Yaseen and Sharma 1995). Similarly, Human herpes virus 8 
(KSHV or HHV8) encodes many oncogenic viral homologues to host 
proteins, which can potentially drive cell proliferation, immune evasion and 
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angiogenesis (Bais et al. 1998, Yang et al. 2000). The two latter viruses, 
unlike HPV, do not integrate into the human genome, but instead they are 
maintained as circular episomes that replicate independently from the host 
cellular chromosomes. 
Hepatitis B and C viruses (HBV, HCV) usually cause hepatocellular liver 
cancer by inducing chronic inflammation in liver cells leading to cirrhosis 
(Ganem and Prince 2004, Colombo et al. 1989). Cirrhosis is a condition in 
which the liver cells are damaged and scared and can no longer function 
properly. Additionally, HBV expresses X antigen (HBx), which promotes 
cell proliferation, and integrates its DNA into the host genome, inducing 
proto-oncogene activation and chromosomal instability (Sung et al. 2012). 
HCV, unlike HBV, is a single stranded RNA virus that uses RNA instead of 
DNA to store its genetic material.  
Human T-lymphotropic virus (HTLV-1) is a retrovirus responsible for a 
subset of adult T-cell leukemias and lymphomas (Boxus and Willems 2009). 
Retroviruses are a subset of RNA viruses that use their own reverse 
transcriptase enzyme to synthesis double strand DNA from RNA and then 
integrate into the host cell using another enzyme called integrase.  
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1.2 The Cancer Genome 
Over a century ago, Theodor Boveri hypothesized that chromosomal 
aberrations may be the underlying factor driving cancer (Boveri 1914). 
Following the discovery of DNA as the genetic material (Avery, Macleod 
and McCarty 1944) and its structure (Watson and Crick 1953), it was shown 
that alterations in DNA could potentially be the driving force behind cancer 
development. The first evidence of a cancer driver alteration was found 
nearly 50 years after Boveri’s hypothesis with the identification of “The 
Philadelphia Chromosome”, as a translocation between chromosome 9 and 
22 in leukemia tumors (Rowley 1973, Nowell 1962). A new protein with 
oncogenic properties was produced fusing two genes, BCR and ABL, as a 
result of this chromosomal rearrangement (Fig. 2). Subsequently it was 
shown that the activation of the h-ras oncogene was associated with a point 
mutation (Reddy et al. 1982). These discoveries led to further investigation of 
cancer-associated genomic alterations, which were functionally important for 
the development of the tumor. 
DNA alterations occur frequently in the human body, where most are 
repaired through a mechanism called DNA repair. However, a small fraction 
of these alterations avoid being repaired, and some of them will give the cell 
Figure 2: The Philadelphia chromosome  
 
Comprehensive analysis of structural genomic alterations in cancer 
 
12 
certain characteristics outlined previously (see section 1.1.3) as the hallmarks 
of cancer (Hanahan and Weinberg 2011a). These alterations that are 
beneficial for the transformation of the normal cell to the tumor cell are 
called “driver events” whereas all the other random alterations in the cellular 
DNA are likely to be “passengers” for the cancer development. 
Somatic alterations in cancer genomes can be divided into several distinct 
classes in terms of size and type. These include point mutations, insertions or 
deletions of small DNA segments (indels), structural variations (SVs), and 
insertions of non-endogenous sequences such as viral DNA (Fig. 3).  
1.2.1 Point mutations and Indels 
The human genome is made up of billions of pairs of nucleotides. Point 
mutations are defined as the substitution of one base pair for another. 
Additionally, indels are defined as small insertions and deletions in the 
cellular DNA. Although point mutations in coding genes result in altered 
DNA sequences, they don’t necessarily change the resulting amino acid 
sequences of the proteins, as multiple nucleotide sequences code for the same 
amino acid. To date, several driver somatic mutations are known to be 
associated with multiple different cancer types (Table 2), sometimes 
Figure 3: Catalogue of somatic alterations in the cancer genome 
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affecting as much as 80% of tumors in a given cancer type (Rubio-Perez et al. 
2015, Gonzalez-Perez et al. 2013). 
Table 2: The most recurrently mutated cancer driver genes. Genes with a gain of 
function mutation (oncogenes) are shown in red whereas the loss of function mutated 
genes (tumor suppressors) are in blue 
1.2.2 Structural Variations 
Structural variations (SVs) are defined as alterations in chromosomal DNA 
typically larger than 1 Kb. Structural variations consist of copy number 
imbalance events such as deletions and duplications, inversions, 
interchromosomal translocations (Fig. 4), transposon insertions, or foreign 
DNA insertions such as viral DNA (Feuk, Carson and Scherer 2006). 
Traditionally, the two later are not classified as SVs even though by 
definition they are variations in the chromosomal structure. 
Symbol %Mutated (Cancers) %Mutated in all cancers 
TP53 > 80 (Ovarian, Lung) > 30 
PIK3CA > 50 (Uterine) > 10 
KRAS > 45 (pancreas, Colorectal) > 5 
BRAF > 50 (Thyroid, Melanoma) > 5 
PTEN > 60 (Uterine) > 5 
MLL3 > 20 (Bladder) > 5 
APC > 75 (Colorectal) > 4 
MLL2 > 20 (Bladder, Lung) > 4 
ARID1A > 25 (Uterine, Bladder) > 4 
NF1 > 10 (Lung, Melanoma) > 4 
Figure 4: Different Types of SVs 
Comprehensive analysis of structural genomic alterations in cancer 
 
14 
Deletions and duplications 
Deletions and duplications are two classes of structural variations that are 
copy number unbalanced. Deletions result in the loss of a genomic region 
whereas an extra copy of a DNA segment is added to the genome through 
duplication (Feuk et al. 2006). Duplications typically happen in two forms: 
(1) Through DNA insertions, in which one fragment of DNA is duplicated 
and inserted into another genome region, as a result of both inter or intra 
chromosomal translocation and (2) through tandem duplications, by which a 
DNA fragment is placed adjacent to itself (McBride et al. 2012). While 
deletions and duplications contribute to cancer development mainly by 
altering copy number of oncogenes and tumor suppressors leading to their 
deregulation, they may also cause gene fusions with novel properties that are 
potentially important in cancer. The most common case of such events is a 
deletion in chromosome 17 causing the activation of the ERG oncogene 
through fusion with the TMPRSS2 gene (Linn et al. 2016). 
Inversions 
Not all SVs lead to DNA copy number alterations (Feuk et al. 2006). 
Inversions are copy number neutral rearrangements in which a segment of 
DNA is reversed end to end within the same chromosome. Inversions will 
usually not influence the genes within the boundaries of the inverted region. 
However, the genes that span the DNA break junctions might be deregulated 
through, for example, the creation of gene fusions. Recurrent inversion events 
involving the RET oncogene, a RTK, in thyroid cancer has previously been 
reported as a mechanism to activate this gene (Cinti et al. 2000). Due to the 
complex nature of these events, not being detectable by CNV detection 
approaches, many potentially important events in cancer are still yet to be 
found. 
Inter-chromosomal translocations  
As discussed above, the first genomic alteration known to be functional in 
cancer was an inter-chromosomal translocation leading to a BCR-ABL 
oncogenic gene fusion (Nowell 1962). Inter-chromosomal translocation is a 
type of rearrangement where two chromosomes break and are fused with 
each other. They can be reciprocal, in which they exchange the broken 
segments and therefore no genomic region is lost or gained, or non-reciprocal 
where only one of the broken segments of DNA in the two chromosomes are 
fused. The result is a DNA copy number loss of the other broken ends of the 
two chromosomes (Rabbitts 1994). Soon after the discovery of the 
Philadelphia chromosome, several other inter-translocations were found to be 
associated with the development of various tumor types (Zech et al. 1976, 
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Oshimura, Freeman and Sandberg 1977, Rowley, Golomb and Dougherty 
1977, Fukuhara et al. 1979). 
Viral Integrations 
As discussed in section 1.1.5, one of the ways that viruses cause cancer is by 
integrating their own DNA into human DNA. HPV and HBV, two big classes 
of oncoviruses, frequently integrate their genome into the human cellular 
DNA. These integrations may lead to the activation of proto-oncogenes such 
as MYC and TERT (Ferber et al. 2003), as well as the expression of viral 
oncogenes including E6 and E7 in HPV (Finzer, Aguilar-Lemarroy and Rosl 
2002). 
Chromothripsis and Chromoplexy 
All SVs mentioned so far were considered to be simple SVs, corresponding 
to one rearrangement in one single event. Chromothripsis on the other hand, 
is a phenomenon whereby a cluster of SVs occurs in a single catastrophic 
event, resulting in highly rearranged chromosomal region (Stephens et al. 
2011). The initial observation was made in myeloid leukemia (Stephens et al. 
2011), but additional chromothripsis cases have been reported in almost all 
cancer types (Rode et al. 2016). Additionally, chromothripsis has been linked 
to poor prognosis, indicating that it may play an important role in 
tumorigenisis (Rode et al. 2016). A relevant phenomenon is chromoplexy 
where random broken chromosome fragments rejoin and result in a balanced 
chain of rearrangements (Shen 2013).  
1.2.3 Relevance of structural variations in cancer  
Somatic SVs may result in amplifications, deletions or rearrangements of 
genomic features such as genes and regulatory elements, all of which could 
alter gene expression and therefore contribute to cancer progression. 
Chromosomal translocations can promote tumor growth through multiple 
mechanisms (1) Creation of novel fusion genes with oncogenic properties; 
(2) Rearrangements of regulatory elements such as gene promoters and 
enhancers leading to abnormal expression of normal cellular genes such as 
proto-oncogenes; (3) Silencing tumor suppressor genes by inducing a 
premature stop codon (Fig. 5). 
Copy number alterations 
SVs often result in copy number variations (CNVs). In cancer genomes, 
tumor suppressor genes are often lost while oncogenes are often copy number 
amplified, sometimes even as much as 1000-fold. High DNA copy number 
amplifications in cancer normally occur in the form of double minute (DM) 
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chromosomes or intra-chromosomal homogeneously staining regions (HSR) 
(Storlazzi et al. 2010). DMs are small fragments of chromosomal DNA 
forming a small circular extrachromosome with no centromere or telomere. 
DMs are not distributed evenly into the daughter cell after mitosis; whereas 
HSR are chromosomal segments that are duplicated many times in a normal 
chromosome and are replicated like the rest of the chromosomal DNA. Both 
typically contain oncogenes that give a selective advantage to the 
development of the tumor. Three frequently amplified oncogenes in cancer, 
MYC, EGFR and ERBB2, are often amplified through the creation of DMs 
and HSRs in various cancer types (Savelyeva and Schwab 2001, Vogt et al. 
2004, Vicario et al. 2015). While tandem duplications and insertions also lead 
to an altered copy number, they are only limited to a one copy increase of the 
amplified DNA.  
Transcriptional deregulation 
The relocation of regulatory elements, particularly promoters, to the vicinity 
of proto-oncogenes is known to be a driving mechanism in cancer. One 
example is “promoter insertion”, observed for the first time in 1981 
(Hayward, Neel and Astrin 1981, Neel et al. 1981), where the activation of 
cellular proto-oncogenes was caused by the insertion of a strong promoter 
(Box 3) from viral DNA into their proximity. A related effect is when a 
genomic translocation leads to a strong promoter in the genome being 
juxtaposed to a weaker promoter of a proto-oncogene (Leder et al. 1983, 
Grimaldi and Meeker 1989, Erikson et al. 1986). These events are typically a 
result of the creation of gene fusions in which the 3’ partner is dysregulated 
by hijacking the 5’ fusion partner promoter (Mertens et al. 2015). The most 
frequent example of upregulation of the 3’ partner by such “promoter 
substitution” is the fusion of several ETS factor proto-oncogenes with 
Figure 5: Mechanisms by which SVs contribute to cancer development. Wavy lines 
represent the amount of mRNA.  
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TMPRSS2 which occurs in more than 50% of prostate tumors leading to 
strong transcriptional activation of the ETS genes (Tomlins et al. 2005).  
Recent studies have shown that enhancers (Box 3), as another class of 
regulatory elements, could in fact have the same consequence in cancer 
genomes (Northcott et al. 2014). This was recently observed in 
medulloblastoma tumors where the activation of several members of the 
GFI1 oncogene family was associated with the juxtaposition of enhancers to 
these genes (Northcott et al. 2014). Both inter-chromosomal and intra-
chromosomal translocations have been shown to contribute to this 
mechanism (Groschel et al. 2014, Weischenfeldt et al. 2017). 
Chimeric genes  
As mentioned in the previous section, gene fusions may result in the 
upregulation of proto-oncogenes; in fact, it was initially believed that the 
functional outcome of the Philadelphia chromosome was the activation of the 
ABL1 gene acting as an oncogene through swapping its promoter with BCR 
gene. However, it was later shown that the result of this translocation was a 
new chimeric gene, which coded a hybrid protein with abnormal oncogenic 
activity (Shtivelman et al. 1985, Stam et al. 1985). Creation of an oncogenic 
fusion protein through the joining of two genes that originally coded for 
different proteins is now a well-known mechanism for the development of 
cancer (Sorensen and Triche 1996, Mertens et al. 2015). 
Box 3. Regulatory elements (Maston, Evans and Green 2006) 
Regulatory elements (REs) are non-coding regions of DNA, which play 
an important role in regulating the transcription process. REs are 
typically upstream of transcription start sites. They include promoters, 
activators and enhancer sequences, all of which promote the expression 
of genes, as well as silencer sequences that inhibit expression.  
Promoters are short sequences located near the transcription start site 
indicating where the transcription of the genes should start. RNA 
polymerase binds to this region and initiates the transcription. Enhancers 
are distal regulatory elements that, by binding to proteins called 
transcription factors, can boost the transcription of a specific gene. 
Enhancers can be located thousands of base pairs away from the 
promoters but, since the DNA is folded and coiled, end up adjacent to 
the promoter in the folded state. 
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Gene truncation 
Point mutations and copy number losses have been discussed as two ways 
that a TS gene can be deactivated. Another mechanism by which a gene can 
become silenced is to manipulate the structure of the gene by introducing SV 
breakpoints leading to the creation of a dysfunctional truncated protein. 
Deactivation of several tumor suppressor genes such as CDKN2A and NF1 
were shown to be through this mechanism (Duro et al. 1996, Storlazzi et al. 
2005). In some cases the structural breakpoint results in the creation of a 
fusion gene, but typically the resulting protein has either a frame shift in the 
reading frame, known as an out-of-frame fusion, or a premature stop codon in 
the novel fusion transcript, both resulting in a dysfunctional protein (Cancer 
Genome Atlas Research et al. 2013). 
1.2.4 Underlying molecular mechanisms of SVs 
Cellular DNA gets damaged at least 10,000 times per day in a given cell (De 
Bont and van Larebeke 2004). These errors include nucleotide damage, 
nucleotide mismatches, and single and double strand breaks. While most of 
these damages gets fixed through multiple mechanisms called DNA repair, a 
small fraction of them, due to imperfect repair, cause mutations and genomic 
rearrangements in the genome. Double strand breaks (DSBs) in particular are 
harmful for the cells since they can lead to creation of SVs. Four major 
mechanisms involving DSB repair may cause SVs in the genome: non-allelic 
homologous recombination (NAHR), non-homologous end joining (NHEJ), 
microhomology mediated end joining (MMEJ), and replication based 
mechanisms (RBMs). 
Non-allelic Homologous Recombination 
Homologous recombination (HR) is a mechanism by which two highly 
similar chromosomes or DNA fragments are exchanged (Capecchi 1989). HR 
based DSB repair involves two identical alleles in which the homologous 
region in one allele is used to repair the same region of the broken DNA of 
the other allele. BRCA1 and BRCA2, two well-known tumor suppressors, are 
required for the HR mediated DSB repair (Venkitaraman 2002) and therefore 
the loss of function mutations in these genes leads to genomic instability and 
eventually cancer. 
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Most recurrent SVs here defined as SVs sharing the same exact genomic 
interval and content, are caused by non-allelic homologous recombination 
(NAHR) (Gu, Zhang and Lupski 2008, Liu et al. 2012). NAHR is a type of 
homologous recombination that connects two highly similar fragments of 
DNA in one allele known as low copy repeats (LCRs) (Shaw and Lupski 
2004) resulting in chromosomal rearrangements. Recurrent SVs are flanked 
by LCRs, which is typically indicative of high homology at the breakpoints. 
Depending on the location and orientation of the LCRs, different types of 
SVs can be introduced in the genome. Recombination between the directly 
oriented LCRs on the same chromosome leads to deletions or duplications, 
whereas inversions happen when two LCRs are on the same chromosome but 
in the opposite direction (Lupski 1998). Additionally, LCRs on different 
chromosomes lead to chromosomal translocations (Fig. 6). 
Non-homologous end joining  
Non-recurrent SVs often have microhomology or small insertions or 
deletions at the breakpoint junctions, which is in contrast with the main 
characteristic of recurrent SVs having extensive homologous sequences (up 
to 10kb) at their breakpoint (Ottaviani, LeCain and Sheer 2014, Carvalho and 
Lupski 2016).  
Non-homologous end joining (NHEJ) is one of the mechanisms used for 
DSB repair, which may result in the creation of non-recurrent SVs (Gu et al. 
2008). In contrast to HR repair, the two broken ends of the DNA are joined 
without relying on a homologous sequence as a template (Moore and Haber 
1996). DSBs typically result in a single stranded DNA overhang on one side 
of the double strand DNA. Incompatible overhang sequences are modified at 
the broken DNA ends, normally causing small deletions or insertions (1-4 bp) 
Figure 6: Intrachromosomal SVs resulted from NAHR. LCRs are shown with 
green arrow where the orientation is shown by the arrowhead. 
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at the joint region 
(Fig. 7) (Lieber 
2008). Finally the 
two broken DNA 
strands are joined 
together using a 
ligase enzyme.  
Micro-homology mediated end joining 
In the absence of NHEJ mechanism in the cell, a more error-prone pathway, 
known as micro-homology mediated end joining (MMEJ) is used to repair 
the induced DSB (McVey and Lee 2008). When a DSB occurs in the cell, 
MMEJ uses 5-25 bp homologous sequences to align two broken DNA 
fragments, therefore a deletion of the same size is introduced at the original 
break site. 
Replication-based mechanisms 
More complex SVs, defined as series of rearrangements which occur in a 
single catastrophic event, cannot be explained by neither NAHR nor NHEJ, 
but replication-based mechanisms are able to explain such events. Break 
induced replication (BIR), is one of these mechanisms that significantly 
contribute to the formation of SVs (Carvalho and Lupski 2016). It is a 
homologous recombination pathway used to repair DSB with only a single 
end, as it happens during the DNA synthesis. Template switching is the main 
mechanism in BIR, where the broken chromosome end invades another 
homologous template and resumes the replication until the next replication 
fork or the end of the chromosome. Defects in this machinery will essentially 
give rise to the creation of different SVs in the genome. Additionally, 
complex SVs can be caused by BIR, given the fact that multiple strand 
invasions can occur during replication (Lee, Carvalho and Lupski 2007, 
Smith, Llorente and Symington 2007, Tsaponina and Haber 2014).  
Breakage-fusion-bridge 
Telomeres are located at the two ends of the chromosomes and are 
responsible for protecting them from degradation or fusion (McEachern, 
Krauskopf and Blackburn 2000). In normal cells, once the telomeres become 
abnormally too short or broken, apoptosis is triggered by p53. However in 
Figure 7: NHEJ may result in small insertion and deletions  
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absence of p53 signaling, the two ends of the unprotected chromosomes may 
fuse together causing genomic instability (Bailey and Murnane 2006). The 
resulting fused chromosomes would have two centromeres and therefore, as 
they are pulled in opposite directions during cell division, the chromosome 
breaks at a random position. This leads to translocations and new uncapped 
chromosome ends. As this process repeats, amplifications and 
rearrangements are formed that accelerate tumor growth (DePinho and 
Polyak 2004). 
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1.3 High Throughput genomic Technologies 
1.3.1 Array-based Technologies 
High throughput microarray-based technologies have revolutionized the 
genetics field (Heller 2002). DNA hybridization, which is the property of two 
complementary DNA strands from different sources binding together, is the 
main principle behind these methods. An array chip is a solid surface in 
which hundreds of single strand DNA probes are spotted. Each spot 
corresponds to a specific DNA fragment and contains millions of copies. A 
fluorescently labeled DNA sample is added to the surface. Different DNA 
fragments in the sample bind to the relevant complementary DNA probes, 
leading to the formation of hybridized double strand DNA molecules. Special 
scanners are then used to quantify the amount of DNA as a measure of light 
emitted from the fluorescently labeled DNA molecules. Array-based 
methods, depending on the probe types, can have distinct applications of 
which the most common application is gene expression profiling (Schena et 
al. 1995). 
Arrays can also be applied to detect CNVs through a technique called array 
comparative genomic hybridization (aCGH) (Solinas-Toldo et al. 1997). 
CGH is a method to quantify CNVs as a measure of DNA content differences 
in a test sample versus a control sample. The intensity signal from the 
differentially labeled test and control samples can be used to identify 
unbalanced chromosomal regions (Kallioniemi et al. 1992). However, CGH 
methods are only capable of identifying big CNVs (> 5 Mb) in the genome. 
Array-based CGH uses the same principle as traditional CGH methods, but 
uses diversely located cloned DNA fragments across the genome (Shaw-
Smith et al. 2004), which lead to the identification of CNVs at higher 
resolutions (> 10 Kb). Multiple aCGH platforms have been developed one of 
which is the Affymetrix “SNP6 array”, with 1 million probes each 
representing a unique position in the genome. 
1.3.2 Sequencing Technologies 
Sequencing is the process of digitally reading the exact order of nucleotides 
in DNA or RNA molecules. The first widely used sequencing approach, 
Sanger sequencing, was developed in 1977 (Sanger, Nicklen and Coulson 
1977). It is based on a method called “chain termination” in which chain-
terminating dideoxynucleotides (ddNTPs) are used to color code each newly 
synthesized DNA with variable length generated from the initial DNA 
molecule. The resulting DNA molecules are then separated by their size and 
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read based on their color representing different nucleotides. This technology 
enabled determination of DNA sequences from any organism, and therefore 
was widely adapted by scientists around the world. However, it is limited in 
regards to speed and scalability, which forced the development of larger scale 
sequencing technologies, later known as next generation sequencing (NGS) 
(Brenner et al. 2000). While NGS allows the sequencing of thousands of 
DNA or RNA molecules simultaneously, Sanger methods are still being used 
as the “golden standard” particularly for the validation of NGS data. 
NGS, also known as high throughput sequencing (HTS), utilizes massively 
parallel approaches to sequence up to millions of bases at the same time. In 
contrast with Sanger sequencing in which only one read is generated for a 
typically large DNA fragment, several reads are generated simultaneously by 
HTS from millions of overlapping small DNA pieces. Nowadays, HTS is 
widely used to sequence the whole genome (WGS), whole exome (WES), 
transcriptome (RNA-Seq), DNA protein interaction (Chip-Seq) and targeted 
genomes (de Magalhaes, Finch and Janssens 2010). The most commonly 
used HTS principle is Illumina/Solexa sequencing, which involves multiple 
steps: First, the DNA sample is sheared into small pieces. Then, special 
adapters are added to the two sides of the DNA fragments allowing them to 
attach to a solid surface. Once the fragments are attached to the surface they 
become amplified, resulting in clonal amplification of all the fragments. 
Fluorescently tagged nucleotides are then used to identify the nucleotide 
sequence producing one read per each fragment. The method is called 
sequencing by synthesis (Goodwin, McPherson and McCombie 2016).  
HTS produces two main types of sequencing data: Single end (SE) and paired 
end (PE). In single end sequencing platforms, DNA fragments are sequenced 
from one end, whereas paired end reads provide reads from both ends of the 
fragments (Buermans and den Dunnen 2014). The relative directionality and 
the probability distribution of the distance between the two reads is 
predefined, which could aid in the prediction of SVs in the genome. 
Furthermore, PE reads are more reliable in the quantification of gene 
expression derived from RNA-Seq since the read pairs can provide more 
precise information about how the genes are spliced. 
 
 
Comprehensive analysis of structural genomic alterations in cancer 
 
24 
1.4 Computational cancer genomics  
1.4.1 Overview  
The assembly of the first human reference genome in 2001 (Venter et al. 
2001) started a new period in biomedical research known as the genomic era. 
The last 15 years have witnessed a drastic increase in the amount of “omics” 
(in particular, genomics and transcriptomics) data being produced, while the 
cost was significantly reduced (Fig. 8). It is estimated that within the next 
decade, this amount would aggregate to 40 exabytes annually (1018 bytes or 1 
million terabytes), much of which is cancer related. Prior to the genomic era, 
all cancer studies used low throughput sequencing in which only a small 
number of genes and mutations were studied together. However, HTS 
provided the opportunity to explore cancer genomes on a much larger scale, 
with many thousands of genes being surveyed together. This has provided 
many new insights into how cancers develop.  
So far, numerous cancer genome projects have been initiated, of which the 
most widely used in cancer research is The Cancer Genome Atlas (TCGA). 
TCGA comprises sequencing data for more than 10,000 patient tumors across 
33 cancer types. To date, several thousand studies have been published using 
these large repositories of sequencing data, leading to the identification of 
several novel driver genomic alterations in cancer (Samuels et al. 2004, 
Levine et al. 2005). For example, pathways not previously associated with 
oncogenesis were also observed to be altered in tumors, one of which was the 
activation of KEAP1/NRF2-signaling pathway, a pathway regulating the 
oxidative stress response in all cells, through the identification of frequent 
mutations in this pathway in lung cancer (Shibata et al. 2008). Additionally, 
Figure 8: DNA sequencing cost and production. Data is taken from the National 
Human Genome Research Institute (https://www.genome.gov/sequencingcostsdata). 
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large-scale cancer genome investigations revealed important insights into 
general patterns of somatic alterations in cancer (Alexandrov et al. 2013, 
Greenman et al. 2007). Similarities and differences between multiple tumor 
types were studied using a combined analysis of large pan-cancer data. For 
example, tumors were classified into copy number or mutation driven 
subtypes based on their molecular profiles (Ciriello et al. 2013).  
Most importantly, these large-scale molecular profiling studies have shown 
promising results in regards to cancer prognosis and diagnosis. Traditionally, 
prognosis of cancer outcome relied on clinical variables such as age and 
tumor stage. Recently, extensive efforts have been made to improve cancer 
prognosis by leveraging molecular information such as tumor genetic 
profiles. This has led to the identification of several biomarkers in different 
cancer types with clinical implications.  
The ultimate goal of cancer genomic studies is to improve treatment and 
diagnostics of cancer. In fact, the impact of different cancer therapies on 
tumor genomes has been investigated extensively during the last decade 
(Hunter et al. 2006, Cahill et al. 2007, Noorani et al. 2017). This has led to 
identification of mechanisms responsible for drug resistance during and after 
different cancer therapies. For example, NRAS and MEK1 activating 
mutations have been shown to be associated with relapsed melanoma tumors 
initially treated with RAF inhibitors (Emery et al. 2009, Nazarian et al. 2010).  
1.4.2 Bioinformatics challenges  
The drastic increase of HTS data has driven the rapid development of 
computational and mathematical approaches by adapting to the increased 
complexity that comes with it. Several challenges have been identified in the 
analysis of large scale sequencing data, one of which is the need for the 
development of specialized tools to detect different classes of genomic 
alterations. During the last decade, various computational methods were 
developed specifically for this purpose. Well-established methods now exist 
for the detection of point mutations and indels (Koboldt et al. 2012, Cibulskis 
et al. 2013), copy number changes (Zare et al. 2017, Li and Olivier 2013), 
genomic rearrangements (Chen et al. 2009, Rausch et al. 2012), and gene 
fusions (Kim and Salzberg 2011, Benelli et al. 2012). 
Another general problem in sequencing data analysis is to distinguish the true 
biologically relevant signal from the technical noise introduced by 
experimental or computational pipelines, such as sequencing artifacts or 
mapping issues. The very first step in analyzing the HTS data is usually to 
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map the sequencing reads to the relevant reference genome. Several methods 
have been developed for such purpose, differing based on the complexity of 
the reference genomes and the quality and type of the sequencing data (Li 
and Durbin 2010, Langmead et al. 2009, Trapnell, Pachter and Salzberg 
2009).  
Additionally, certain challenges are specifically related to cancer genomes. 
Cancer is typically driven by somatic genomic alterations and therefore 
simultaneous analysis of tumor and patient-matched normal pairs are needed 
to identify such events. However, not all somatic alterations are involved in 
cancer development, and most of them are so called “passengers” with no 
impact on the tumor. Identification of driver events that contribute to cancer 
development is yet another challenge in large-scale cancer genomic studies. 
Many mathematical and probabilistic models have been developed to detect 
somatic events in tumor genomes (Meyerson, Gabriel and Getz 2010), all 
based on the presence of the event in the tumor cells and absence in the 
paired matching normal.  
Generally, experimental validation is needed to ensure the functional 
relevance of genomic events in cancer. However, computational approaches 
have been employed to identify potential driver somatic events. These 
methods mainly rely on the recurrence of genomic events across tumor types 
as an indication of positive selection, and the functional impact of individual 
mutations or clusters of mutations within the same cancer pathway (Dees et 
al. 2012, Gonzalez-Perez and Lopez-Bigas 2012, Tamborero, Gonzalez-Perez 
and Lopez-Bigas 2013, Mermel et al. 2011). 
1.4.3 Approaches to SV detection 
Initially, genomic SVs were detected using cytogenetic approaches such as 
fluorescence in situ hybridization (FISH) (Feuk et al. 2006). However, the 
low resolution and throughput of this method only allowed the identification 
of specifically large and simple SVs in the complex tumor genomes. While 
later microarray-based approaches such as aCGH made significant advances 
in the detection of CNVs (Olshen et al. 2004, Yau et al. 2010), they were still 
not capable of detecting balanced SVs such as inversions and translocations. 
Furthermore, they had low resolution in regards to the breakpoint locations.  
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The development of sequencing technologies provided a unique opportunity 
to map SVs with the highest resolution possible, base pair resolution. During 
the last decade, sequencing data, including WES and more recently WGS, 
has been the primary tool for SV detection. While WES is restricted to the 
detection of rearrangements within or near exons, WGS is the most revealing 
but costly approach to detect such events. Furthermore, RNA-Seq can be 
used for the same purpose, but is limited to the detection of alterations 
involving transcribed regions, and would typically fail to detect cases 
involving noncoding or not expressed parts of the genome. Four main 
approaches have been developed to identify SVs using HTS data (Medvedev, 
Stanciu and Brudno 2009): Read pairs (RP), Split reads (SR), Read depth 
(RD), and Contig assembly (CA) (Fig. 9).  
Paired-end reads approach 
Once the short reads are mapped to the reference genome, the chromosome 
positions and strands of the short reads are determined. Depending on the 
sequencing platform, read pairs should have a fixed directionality and 
insertion size. For example, conventional paired-end Illumina sequencing 
reads are typically aligned in forward reverse (FR) order. The short insertion 
size means that the forward read is aligned at a lower coordinate than the 
reverse read, and the mate reads in a pair are usually < 1 kb apart from each 
other, which should be the case for a concordantly mapped pair. However, 
anomalously mapped read pairs in the genome often have an unusual 
signature, such as incorrect mates orientation (e.g. RF or RR for Illumina) or 
abnormal insertion size (e.g. mates mapped to different chromosomes) 
indicative of possible SVs in the genome.  
Figure 9: Approaches to detect SVs. Dashed lines connects two mates in a pair. 
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Discordant read pairs create different unique signatures corresponding to 
different classes of SVs. The most commonly detected signature is the 
“simple deletion” signature, where the mates are mapped in the right 
orientation but with a larger mapping distance than the expected insertion 
size (Medvedev et al. 2009). Conversely, smaller mapping distance 
corresponds to a genomic insertion (Fig 9). Additionally, if the mates in a 
pair are mapped to different chromosomes, it is considered as an inter-
chromosomal translocation signature. All the signatures mentioned so far rely 
solely on abnormal mapping distance. However, tandem duplications and 
inversions would have more complex signatures, where the orientation of the 
mates is also taken into account. Assuming the reads are derived from FR 
sequencing platform, a RF mapped pair can be indicative of tandem 
duplication, whereas FF or RR pairs could correspond to inversions in the 
genome (Fig. 10) (Medvedev et al. 2009). The combination of these simple 
signatures can be used to detect more complex SVs (Yang et al. 2013a).  
Several tools have been developed based on the RP approach (Sindi et al. 
2009, Sindi et al. 2012, Chen et al. 2009). While SV detection using this 
approach is relatively reliable and fast, it is unable to detect the exact 
breakpoints of the SVs. Therefore, combining it with other approaches 
capable of precise breakpoint identification could be ideal for this purpose.  
Split reads approach 
SV in the genome are not only supported by read pairs bridging the two 
breakpoints of the event, but also by single reads spanning each breakpoint 
with a “split mapping” signature. Split mapping reads are defined as reads 
that are partially mapped to one location and partially to the other. They can 
be used to detect SVs with base pair precision. However, split read alignment 
would typically require more computational time and resources compared to 
normal short read alignments, therefore it is less feasible to do on a large 
Figure 10: RP signatures corresponding to different intra-chromosomal SVs adapted 
from Yang et al (Yang et al. 2013a) 
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scale. Due to this limitation, only a few tools have been developed using 
merely SR approach (Suzuki et al. 2011, Wang et al. 2011). However, hybrid 
approaches using the two, PR and SR, have been widely used and have 
shown promising results. Typically, PR approaches are used to identify 
candidate SVs that are later validated and fine tuned using the SR approach 
(Yang, Chockalingam and Aluru 2013b, Rausch et al. 2012, Yang et al. 
2013a, Newman et al. 2014). 
Read depth approach 
With the assumption that the genome is sequenced uniformly, the number of 
reads mapped to different regions should be proportional to the actual copy 
number of that region. For example, a deleted region would typically have 
less reads compared to a neutral region, whereas duplicated regions would be 
associated with a higher number of reads. Thus, the read-depth feature can be 
used to detect SVs (Bailey et al. 2002, Campbell et al. 2008), but it is 
extremely limited compared to the two approaches mentioned above. First, it 
can only detect unbalanced SVs such as deletions and duplications. Second, 
the exact structural basis is not always evident. For example, the duplication 
signature does not specify where the duplication happens but rather what the 
duplicated sequence is. Additionally, the RD approach is incapable of high-
resolution identification of SV breakpoints. Even though the RD approach is 
poorer compared to the other methods for SV detection, it is sometimes used 
in combination with the other tools to better annotate the predicted SVs 
(Sindi et al. 2012). 
Contig assembly approach 
All the methods discussed so far rely on the direct mapping of short reads to 
the reference genome. However, due to the complexity of the human genome 
and specifically cancer genomes, it is not always possible to accurately map 
short reads to the reference genome. Another approach that has been 
proposed for SV detection is to assemble the short reads into contigs or 
longer sequences independent of the reference genome, and then map them to 
the genome. Several tools have been implemented using this approach, which 
are often computationally inefficient (Mohiyuddin et al. 2015, Chen et al. 
2014). However, similar to SR approach, base pair resolution of SV 
breakpoints is achievable by CA and therefore can be combined with more 
efficient methods for better characterization of SVs in the genome (Schroder 
et al. 2014).  
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2 AIMS 
The main objective of this thesis was to comprehensively investigate SVs 
such as viral integrations and inter- and intra-chromosomal rearrangements, 
and their impact on the tumor transcriptome. Computational approaches were 
applied to cancer genomics data to answer biologically relevant questions. 
RNA-Seq and SNP6 based copy number data from ~10,000 tumors, and 
WGS data of 600 tumor normal pairs (each > 75 Gb) were used in this thesis, 
all of which aggregated to >200 Tb of data.  
More specifically, the objectives were:  
• To provide a complete map of different classes of SVs in 
cancer genomes with the help of WGS data (Papers I, II, 
III) 
• To investigate the association between SVs and gene 
expression levels (Papers I, II, II) 
• To highlight specific cases with potential functional 
implications in cancer (Papers I, II, II) 
• To identify viral integration sites in cancer genomes (Paper 
I) 
• To explore the relationship between SVs and CNAs (Papers 
II, III) 
• To use a dual DNA/RNA approach to provide a high 
confidence set of gene fusions in cancer (Papers II, III) 
• To identify intra-chromosomal SVs in a larger cohort with 
the help of array-based copy number data (Paper III) 
• To find potentially functional intra-chromosomal SVs that 
lead to oncogene activation through promoter substitution 
(Paper III) 
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3 RESULTS AND DISCUSSION  
3.1 Tumor-virus associations (Paper I) 
Tumor-virus associations have been extensively studied in a few cancer types 
mostly using low throughput approaches. The availability of tumor 
sequencing data provides an opportunity to survey the relevance of viral 
associations in diverse cancer types. Here, a systematic screen for viral 
expression was performed using 4,433 tumors across 19 tumor types, and 
viral integration sites were identified in virus positive tumors. 
The discordant read pair approach has been widely used to detect SVs in the 
human genome. In principle, the same approach can be used to detect foreign 
DNA insertions, such as viral DNA, into the human genome. In this context, 
discordant read pairs refer to pairs that have one mate mapping to the human 
genome and the other to the viral DNA. Integrated viral DNA with a possible 
functional role is often expressed, and therefore discordant reads should also 
reveal themselves in RNA-Seq data (Fig. 11).  
A pipeline was first developed to identify virus positive tumors by measuring 
the viral expression in tumors. This was performed by counting the number 
of reads that mapped to the viral genome and not to the human genome, 
normalized for the library size and indicated as parts per million (p.p.m.). 
Viral expression was observed in 178 tumors (> 2 p.p.m), of which 150 cases 
(84.2%) were HPV and HBV positive. As expected, HPV was dominantly 
observed in cervical (Clifford et al. 2006) followed by head and neck tumors 
(Mork et al. 2001) (96.6% and 14.1% respectively), whereas HBV infected 
tumors were only seen in hepatocellular cancer (11 tumors, 32.4%) at the 
Figure 11: Schematic of viral-human fusion; Discordant read pairs are shown in 
the brown boxes 
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selected level of stringency. The remaining infected viruses such as herpes 
viruses were mostly non-driver events with no active role in tumor 
development. However, one bladder tumor showed high expression of BK 
virus (BKV), specifically its known oncogene (Tag), which further supported 
the previously proposed aetiological role of this virus in tumor formation 
(Abend, Jiang and Imperiale 2009). 
Next, a viral integration pipeline was developed based on the discordant read 
pair principle, and applied to the virus positive cases. Only integrations 
supported by multiple discordant read pairs where the human mates were 
clustered together in a genomic region were considered. Confirming previous 
studies (Schmitz et al. 2012, Sung et al. 2012), viral integrations were 
observed in most HPV and HBV positive tumors (104 tumors; 70%). 
Additionally one BKV positive bladder tumor had evidence of viral 
integration on chromosome 2.  
Figure 12: Viral integration sites randomly distributed across the genome. Number 
of integrations for each chromosomal cytoband is shown here. Selected genes are 
shown for cytobands with recurrent integrations. 
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While viral integration sites were widely spread across the genome, regions 
with recurrent viral integrations mostly contained known cancer genes or 
previously described fusions sites (Fig. 12). The most recurrent integration 
was HPV insertion in the MYC locus, previously described as a known HPV 
fusion site in cervical cancer (Peter et al. 2006). HPV was recurrently fused 
with PVT1 and LOC727677, two long non-coding RNAs downstream and 
upstream of MYC (four and three cases respectively), all of which were 
associated with elevated expression levels of these genes. Another 
confirmatory observation was the recurrent HBV integration with MLL4 in 
hepatocellular cancer (n = 3), which was associated with overexpression of 
this gene (Sung et al. 2012).  
Notable among the novel findings, two cervical tumors had an HPV insertion 
in ERBB2, one of which showed strong ERBB2 induction. Moreover, several 
cervical tumors had RAD51B-HPV fusion (n = 4), resulting in weak reduction 
of RAD51B expression, a gene involved in DNA DSB repair. Loss of 
RAD51B protein function has been shown to contribute to tumor growth by 
inducing genomic instability (Suwaki, Klare and Tarsounas 2011). Our novel 
findings regarding HPV integration sites in cervical and head and neck 
tumors using HTS data, show that HPV integration into cellular DNA may 
play a role in oncogenesis, not only by expressing HPV viral oncogenes 
including E6 and E7, but also by altering the activity of cellular oncogenes 
and tumors suppressors such as ERBB2 and RAD51B.  
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3.2 Mapping of Somatic SVs across multiple 
cancer types (Papers II, III) 
In this part of the thesis, intra-cellular SVs were identified using WGS data 
(Paper II) and SNP6 copy number profiles (Paper III).  
3.2.1 Mapping SVs using WGS data 
The availability of a large amount of WGS data in TCGA made it possible to 
carefully map somatic SVs in several hundreds of tumor genomes. First and 
foremost, a computationally and biologically robust WGS-based pipeline 
capable of high-resolution identification of these events was needed. Unlike 
inter-cellular SVs such as viral insertions, several tools had previously 
developed for this purpose. Thus, we decided to employ the already available 
tools instead of implementing our own method. However, large discrepancies 
between different tools were observed after applying them to WGS data, and 
therefore a careful assessment of different SV callers was required. 
Benchmarking SVs has been challenging for several reasons, one of which is 
the lack of golden standard data to objectively evaluate different SV callers. 
While simulated human genomes have been widely used for this purpose 
(Qin et al. 2015, Bartenhagen and Dugas 2013, Hu et al. 2012, Korbel et al. 
2009), the true complexity of cancer genomes is not fully reflected using 
simulated data. As copy number changes are ideally a subset of SVs, a 
perfect SV detection tool should be able to detect them. Thus, array-based 
CNV data could be used as true positive set to assess WGS based SVs 
obtained from different SV callers. 
Four SV caller tools – SVDetect (Zeitouni et al. 2010), BreakDancer (Chen 
et al. 2009), Delly (Rausch et al. 2012), and Meerkat (Yang et al. 2013a) - 
were primarily selected for further evaluation. All four made use of the PR 
approach to identify regions with potential SVs. While SVDetect purely 
relies on this method, Meerkat and Delly combine it the SR approach for a 
more precise identification of SVs with base pair resolution. Additionally, 
BreakDancer uses the RD approach specifically for accurate characterization 
of copy number imbalance SVs.  
Next, the sensitivity and specificity of the four SV callers were measured 
using true and randomized CNV breakpoints as true and false positive sets 
respectively. Meerkat had the best performance considering both sensitivity 
and specificity scores, and therefore was selected as the primary SV detection 
tool. Finally, somatic SVs were mapped in 600 tumors across 18 cancer types 
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using high coverage WGS data. This provided the most comprehensive map 
of somatic SVs in cancer to date.  
3.2.2 CNVs as a subset of SVs  
Having access to base-pair resolution SVs from WGS as well as CNV data 
derived from the Affymetrix SNP6 platform for 600 tumor genomes provided 
a unique opportunity to systematically investigate the relationship between 
SVs and CNVs, which have typically been studied in isolation (Paper II). At 
the breakpoint level, the two correlated considerably in terms of absolute 
number of breakpoints within different tumors (Pearson’s r = 0.81). 
Additionally, even though a small fraction of CNV events had a 
correspondence in SV data (~10%), the overlapping set was mostly classified 
correctly where 97% and 90% of copy number losses and gains were 
categorized as deletions and tandem duplications respectively. As array-based 
CNVs data is still considerably more abundant than WGS data, it is temping 
to use it as a substitute to identify genomic rearrangement caused by SVs in 
the genome. However, it should be noted that this only represents a small 
fraction of SVs that are copy number imbalanced, and therefore WGS data, 
when available, is highly favorable over array-based data.  
In TCGA, high coverage WGS data is available for 600 tumors, while SNP6 
copy number profiles are available for ~10,000 tumors. Thus, a 
comprehensive analysis of a subset of SVs in an even a larger set of tumors 
was possible. In Paper III, deletions and tandem duplications were 
categorized as CNVs with a clear interpretation in terms of their structural 
basis. For example, only genomic regions with one extra copy and no gained 
adjacent regions were considered as tandem duplication. Using this strict 
filtering on CNV data, we were able to provide a catalogue of simple 
deletions and tandem duplications in a large cancer cohort.  
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3.3 Impact of somatic SVs on tumor RNA (Papers 
II, III) 
As it follows from the central dogma of molecular biology, a genomic 
alteration that has a functional role during tumor development should also 
have an impact on the RNA produced by the cell. SVs contribute to cancer 
development by multiple different mechanisms (see section 1.2.3), all of 
which have a direct impact on tumor RNA by either altering the mRNA 
levels, for example by promoter substitution; or altering the mRNA structure 
by forming new chimeric transcripts. In this part of the thesis, the global 
impact of somatic SVs on tumor RNA, using both expression levels and 
structure, was explored. Candidate tumor driver events with an impact on 
tumor transcriptional output were highlighted (Papers II, III). 
3.3.1 Promoter substitutions 
A well-established mechanism for gene activation by SVs is to substitute a 
weak promoter of a gene for a stronger promoter of another, which usually 
occurs as a result of the two genes being fused together. As mentioned in 
section 1.2.3, activation of individual oncogenes through promoter 
substitution (PS) has been previously described for several cases in cancer 
(Tomlins et al. 2005, Oliveira et al. 2005). However, it is still unclear how 
often such events occur in tumors and to what extent they have an impact on 
tumor transcriptional output. To systematically investigate these cases in 
cancer, we used SV calls, from both WGS (Paper II) and SNP6 (Paper III) 
data, to identify cases that may result in the creation of PS events. Only SVs 
resulting in chimeric gene regions where the promoter of the 3’ partner was 
substituted for the 5’ partner promoter were considered. In both studies, we 
observed that mRNA of the 3’ partner was more in induced when the 5’ 
partner had the stronger promoter rather than the weaker one.  
In Paper II, 62 PS events were found where the 3’ partner was significantly 
induced (>3 fold), of which only two cases were recurrent within one cancer 
type, both being previously described. These cases included activation of 
ERG and RET in prostate and thyroid cancers, through the hijacking of the 
strong promoters of TMPRSS2 and CCDC6, respectively. Notable among the 
non-recurrent cases was strong induction of PRKCB, a protein kinase C gene, 
observed in one colorectal tumor through a PS event with USP7, a gene 
typically highly expressed in colorectal carcinoma. This resulted from an 
inversion on chromosome 16, creating a fusion transcript where the two 
promoters are swapped (Fig. 13). Frequent fusions involving genes in protein 
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kinase C family such as PRKCA and PRKCB, have been previously described 
in different tumors, and are mostly associated with gene activation (Stransky 
et al. 2014, Bridge et al. 2013, Plaszczyca et al. 2014). Taken together, 
although it remains unclear to what extent such events are under positive 
selection and functional in cancer, results from this study suggest that PS 
often contribute to gene activations in cancer.  
Rare driver events in cancer occur at low rate and therefore are only 
observable when a large enough set of tumors is being analyzed. This 
motivated us to make use of SVs calls derived from SNP6 copy number 
profiles (Paper III), available for a larger set of tumors (~10,000), to identify 
more recurrent PS affected cases. 126 repeated (n >=2) cases showed 
evidence of PS where the 3’ partner was induced within the same cancer type 
(2-fold). 
Notable among the significantly induced cases (n = 8; FDR 10%), was strong 
induction of TIAM2 in five ovarian and one uterine tumors through PS with 
SCAF8, a nearby gene that shows strong promoter activity in ovary and 
uterus tissue types. This resulted from a genomic deletion on chromosome 6, 
juxtaposing the SCAF8 promoter to the TIAM2 promoter region, upstream of 
the transcription start site (Fig 14). T-cell lymphoma invasion and metastasis 
genes (TIAM1, TIAM2) act as regulators in the Rac GTPase pathway, an 
important signaling pathway in cancer (Parri and Chiarugi 2010). While the 
significance of TIAM genes in cancer is well established (Liu et al. 2007, 
Wang and Wang 2012, Zhao et al. 2013), the underlying molecular 
mechanism of their activation is poorly understood. Here, we propose a novel 
mechanism for TIAM2 activation; however, further investigation is needed to 
establish that the fusion transcript is translatable into TIAM2 protein and to 
determine the functional relevance of increased TIAM2 protein levels in these 
tumors. 
Figure 13 Strong promoter of USP7 (indicated by big blue arrow) is swapped with 
the weak promoter of PRKCB (indicated by small red arrow) through an inversion in 
chromosome 16. 
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Additionally, we found that SCARB1 mRNA was induced through hijacking 
of the promoter of NCOR2, an adjacent gene with high expression in these 
tumors, in stomach, esophageal, and lung adenocarcinoma. On the DNA 
level, this results from a tandem duplication by which an additional fusion 
transcript is formed. While the functional domain of SCARB1 (CD36) is 
maintained in the new chimeric gene, the 5’ end including the promoter 
region is replaced with the 5’ end of NCOR2 (Fig 15). Overexpression of 
scavenger receptor class B (SCARB1) is known to be associated cancer 
development. Additionally, a recent study has shown that CD36 is required 
for the acquisition of metastatic phenotypes in the cell, therefore could be 
used as a possible target for anti-cancer drugs (Pascual et al. 2017). 
Figure 15: Strong promoter of SCAF8 is brought to the proximity of TIAM2 by 
genomic deletions. Blue boxes correspond to deletions in different tumors. 
Figure 14: SCARB1 overexpression by hijacking the strong promoter of NCOR2. 
The red boxes represent the tandem duplications in different tumors.  
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Taken together, we observed that all classes of SVs, including deletions, 
tandem duplications and inversions, are involved in transcriptional activation 
of cancer-relevant genes through hijacking of strong promoters from other 
cellular genes.  
3.3.2 Enhancer Hijacking  
PS is not the only way that SVs cause transcriptional deregulation in tumors. 
Recent studies have demonstrated that mRNA induction can occur as a 
consequence of rearrangements of noncoding cis-regulatory elements such as 
enhancers, without altering the mRNA structure (Northcott et al. 2014, Affer 
et al. 2014). During the last decade, with the availability of more WGS data, 
noncoding genomic alterations were studied more comprehensively as a way 
of activating cancer driver genes. The most frequent case to date is the TERT 
promoter mutation described in several cancer types, which is typically 
associated with TERT elevated expression (Huang et al. 2013, Fredriksson et 
al. 2014). Additionally, activating SVs upstream of the TERT transcription 
start site resulting in juxtaposition of enhancers to the TERT promoter region 
has been described in kidney chromophobe tumors (Davis et al. 2014). This 
motivated us to systematically investigate the impact of upstream SVs on the 
tumor transcriptome. In Paper II, elevated expression levels associated with 
upstream SVs were observed in 39 genes. Among those were TERT promoter 
proximal SVs identified in kidney renal, colorectal and melanoma, most of 
which led to TERT overexpression. Our results further established the role of 
SVs involving regulatory elements in tumor transcriptional induction.  
3.3.3 Fusion genes  
SVs may lead to the juxtaposition of two genes and hence the creation of a 
fusion gene. Gene fusions are now recognized as one of the most common 
driver alterations in cancer. Another way by which these events could 
contribute to tumorigenesis, in addition to promoter substitution, is to create a 
chimeric transcript with a novel oncogenic function that is different from the 
individual fusion partner genes (see section 1.2.3). 
Large-scale gene fusion investigations are mostly based on RNA-Seq data, 
due to the low cost of RNA-Seq in comparison to WGS data. Functional gene 
fusions in cancer are usually expressed in the tumor and theoretically should 
be detectable by RNA-Seq data. However, that is not always the case in 
reality and many fusion detection tools fail to identify expressed fusion 
transcripts. One study demonstrated that large variability between different 
RNA-Seq based algorithms exist (Carrara et al. 2013), indicative of the large 
number of false positives and negatives in the data. Additionally, even for 
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correctly characterized fusion genes, the genomic structural basis of such 
events cannot be determined using RNA-Seq data. Having access to SV calls 
for many tumors provided a unique opportunity to investigate gene fusions 
using a more informative dataset. However, similar to RNA-Seq data, the 
sensitivity and specificity of such data is low (see section 3.2.1). 
Nevertheless, as the two data types are generated independently, presumably 
they do not share the same artifacts. Thus, the integration of both DNA-based 
and RNA-based fusion calls could in principle provide a more sensitive and 
specific set of gene fusions (Paper II).  
First, fusions were identified in tumors with both WGS and RNA-seq data 
(431 samples) independently. SVs where the two breakpoints spanned two 
distinct genes with the correct orientation based on the SV type were 
considered as valid gene fusions (5,209 events). In parallel, fusion transcripts 
were identified using an RNA-Seq fusion detection tool (9,657 events). 
Surprisingly, only 299 gene pairs were found to be common in DNA and 
RNA calls. We next assessed if the sensitivity was reduced in the combined 
set in regard to identifying potential driver events in cancer. Strong 
enrichment of known cancer-associated genes was observed in the combined 
approach compared to the two approaches separately. These results indicated 
that the dual approach could be beneficial in identifying cancer driver events. 
Taken together, we show that a more reliable set of fusions in cancer can be 
achieved by using both DNA and RNA data together.  
Notable among the high confidence set of fusions was a fusion involving 
NRF2 gene in one thyroid tumor. NRF2 is a transcription factor, which is a 
key regulator in the cellular oxidative stress response pathway. In normal 
cells, NRF2 protein remains inactive due to binding to a repressor protein 
called KEAP1. Conversely, in cancer cells, the NRF2-KEAP1 interaction is 
frequently disrupted leading to the activation of NRF2 (Kansanen et al. 
2013). Several mechanisms are known to be involved in the deregulation of 
the NRF2 signaling pathway in cancer including mutations in KEAP1 (Ohta 
et al. 2008), mutations in the KEAP1 binding domain of NRF2 (Shibata et al. 
2008), or KEAP1 hypermethylation (Hanada et al. 2012). Here we observed 
transcriptional induction of NRF2 through fusion with PAX8, as a 
consequence of a tandem duplication in chromosome 2 (Fig. 16). Additional 
observations, including the loss of the KEAP1 interaction domain of NRF2 in 
the new fusion transcript, and strong induction of several known NRF2 
targets, further supported the functional role of this fusion in the activation of 
NRF2 pathway.  
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In summary, through integrative analysis of genomic and transcriptomic data 
from a large cancer cohort, multiple insights into the relevance of SVs in 
cancer including the relationship between genomic SVs, CNVs and gene 
expression were provided.  
  
Figure 16: Activation of NRF2 by PAX8-NRF2 fusion as a result of a tandem 
duplication  
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4  CONCLUSIONS AND FUTURE 
PERSPECTIVES 
This thesis provides a comprehensive catalogue of simple structural genomic 
alterations in cancer. Bioinformatical approaches were developed to 
systematically investigate the role of such alterations in cancer, and several 
potentially functional events were highlighted.  
Despite unprecedented progress in the identification and analysis of SVs in 
cancer, providing a complete map remains challenging. One of the main 
challenges is to identify more complex types of SVs such as choromothripsis 
and chromplexy, where large number of structural changes arises in a single 
event (see section 1.2.2). Both chromoplexy and chromothripsis have been 
observed in individual cancer types, but it is not yet fully understood how 
these events contribute to tumor progression. The main limitation here is the 
imperfect mapping of these complex events, which can be improved by 
obtaining longer reads. This can be partially solved by assembly of short read 
sequences into longer contigs, as this data is already available for thousands 
of tumors. Furthermore, while recent studies have tried to infer the 
underlying mechanisms of somatic SVs in the genome, the molecular 
mechanism for many of these events is still yet to be determined. Given the 
distinct genomic signatures of such mechanisms of SV formation, 
investigating general patterns of SVs in several tumor genomes could aid to 
understand the mechanisms by which these genomics alterations occur.  
Numerous clinically relevant driver events have been found during recent 
decades, using both low and high-throughput approaches. HTS has 
empowered the detection of less frequent genomic events that could not be 
detected with the small number of samples being analyzed. By applying 
methods such as those described in this thesis to even larger cohorts, it is 
likely that additionally functional events, that may not be frequent enough to 
identify as recurrent in currently available datasets, can be pinpointed.  
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